Lunai Bioworks (NASDAQ: LNAI) furloughs staff while seeking new financing

Rhea-AI Filing Summary

Lunai Bioworks, Inc. reported that on February 27, 2026 it implemented a temporary furlough of employees in the United States and Canada to help preserve liquidity while it pursues additional financing. Furloughed employees will not work for the company or receive compensation, subject to applicable laws and contracts.

The company describes the furlough as temporary, but its length depends on securing additional capital. The Chief Executive Officer and Chief Financial Officer have voluntarily agreed to temporarily defer their salaries without changing their employment terms. Lunai Bioworks is maintaining limited operations and has begun recalling certain operational employees to support ongoing platform development, with further recalls planned as circumstances permit.

Positive

• None.

Negative

• Temporary employee furloughs to preserve liquidity: Lunai Bioworks has furloughed its U.S. and Canadian employees, halting their work and pay while it seeks additional financing, signaling heightened focus on cash conservation and operational scaling back.

Insights

Distressed & special situations analyst

Lunai Bioworks is cutting payroll via furloughs while seeking new capital.

Lunai Bioworks has temporarily furloughed its U.S. and Canadian employees as part of measures to preserve liquidity while it seeks additional financing. During this furlough, affected staff will not work or be paid, subject to legal and contractual requirements.

The company states the furlough is intended to be temporary, with its duration tied to the success of capital-raising efforts. The voluntary salary deferral by the CEO and CFO underscores a focus on conserving cash without formally changing their employment terms.

Lunai is keeping limited operations running and has already started recalling certain operational employees to support platform development and related programs. It plans to recall further employees as conditions allow, so future disclosures about financing progress and workforce status will be important context for assessing operational momentum.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Understanding 8-K Material Events →

false 0001527728 0001527728 2026-02-27 2026-02-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
 Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities ExchangeAct of 1934

Date of Report (Date of earliest event reported): February 27, 2026

LUNAI BIOWORKS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38751		45-2259340
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

3400 Cottage Way, Suite G2, #3256

Sacramento, California 95825

(Address of principal executive offices)

+1 (424) 222-9301

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of theAct:

Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share		LNAI		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities ExchangeAct of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the ExchangeAct. ☐

Item 8.01 Other Events.

On February 27, 2026, Lunai Bioworks Inc. (the “Company”) implemented a temporary furlough of its employees in the United States and Canada as part of actions intended to preserve the Company’s liquidity while it continues to pursue additional financing.

During the furlough period, affected employees will not perform services for the Company and will not receive compensation, subject to applicable laws and contractual obligations. The Company intends for the furlough to be temporary; however, the duration of the furlough will depend on the Company’s ability to secure additional capital.

In addition, the Company’s Chief Executive Officer and Chief Financial Officer have voluntarily agreed to temporarily defer payment of their salaries during this period. This deferral does not modify the terms of their respective employment arrangements.

The Company continues to maintain limited operations, remains engaged in efforts to secure additional capital, and has begun recalling certain operational employees from furlough to support ongoing platform development and related programs. The Company intends to recall additional employees as circumstances permit.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	LUNAI BIOWORKS, INC.
	By:	/s/ David Weinstein
	Name:	David Weinstein
	Title:	Chief Executive Officer
Date: March 5, 2026

FAQ

Why did Lunai Bioworks (LNAI) implement an employee furlough?

Lunai Bioworks implemented a temporary furlough of its U.S. and Canadian employees to help preserve liquidity while it pursues additional financing. The company links the length of this furlough directly to its ability to secure additional capital.

How long will Lunai Bioworks’ employee furlough last?

Lunai Bioworks describes the furlough as temporary, with its duration depending on the company’s success in securing additional capital. There is no fixed end date; the timeline is tied to future financing progress.

Are Lunai Bioworks employees paid during the furlough?

During the furlough, affected Lunai Bioworks employees will not perform services and will not receive compensation, subject to applicable laws and contractual obligations. This creates immediate payroll savings while the company focuses on obtaining additional financing.

What actions are Lunai Bioworks’ executives taking during the furlough?

Lunai Bioworks’ Chief Executive Officer and Chief Financial Officer have voluntarily agreed to temporarily defer payment of their salaries during the furlough period. The company notes that this deferral does not change the underlying terms of their employment arrangements.

Is Lunai Bioworks still operating during the furlough?

Lunai Bioworks states that it maintains limited operations and continues efforts to secure additional capital. It has begun recalling certain operational employees from furlough to support ongoing platform development and related programs, with more recalls planned as circumstances permit.

How does the furlough affect Lunai Bioworks’ plans for future staffing?

Lunai Bioworks indicates it has already started recalling some operational employees from furlough to support platform development. The company intends to recall additional employees over time, but emphasizes that further recalls depend on circumstances, including obtaining additional financing.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB